长程低剂量口服Vp-16治疗晚期肺癌17例近期效疗观察

应用长程低剂量口服足叶乙甙（Ｖｐ－１６）治疗晚期肺癌１７例，ＰＲ为２３．５２％（４／１７），ＮＣ３５．２９％（６／１７）；毒副作用主要为骨髓抑制、恶心、呕吐和脱发，但均为轻度及可逆性反应。长程低剂量口服Ｖｐ－１６对失去手术机会或术后复发、转移而不能耐受正规静脉化疗的晚期肺癌患者是较理想的治疗方法。

Short-Term Response of Advanced Lung Cancer Treated with Prolonged Oral Administration of Vp 16

Seventeen cases of advanced lung cancer were treated with prolonged oral administration of Vp 16 and the response was PR23.52%, NC 35.29%. Major side efefects were myelosuppression, alopecia , nausea and vomiting . They were all mild and tloerable.Authors suggested that prologed oral administration of Vp 16 be used as a useful approach in the treatment of the advnaced lung cancer.